Shasun Pharmaceuticals gets nod for preferential allotment to OrbiMed

23 Mar 2012 Evaluate

Shasun Pharmaceuticals has received its board’s approval for the preferential allotment to Caduceus Mauritius Asia (CAML), a wholly owned subsidiary of OrbiMed Asia Partners. The company will allot 65,78,947 equity shares at Rs 76 per share, aggregating to Rs 50 crore.

OrbiMed is the world’s largest healthcare dedicated investment firm, with about $5 billion in assets under management.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×